Titre : Alcaloïdes de Vinca

Alcaloïdes de Vinca : Questions médicales fréquentes

Termes MeSH sélectionnés :

Single-Cell Analysis
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Alcaloïdes de Vinca : Questions médicales les plus fréquentes", "headline": "Alcaloïdes de Vinca : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Alcaloïdes de Vinca : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-01-08", "dateModified": "2025-04-02", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Alcaloïdes de Vinca" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Alcaloïdes formés par condensation de sécologanine et de tryptamine", "url": "https://questionsmedicales.fr/mesh/D046948", "about": { "@type": "MedicalCondition", "name": "Alcaloïdes formés par condensation de sécologanine et de tryptamine", "code": { "@type": "MedicalCode", "code": "D046948", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.496.500.500.681" } } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Vinblastine", "alternateName": "Vinblastine", "url": "https://questionsmedicales.fr/mesh/D014747", "about": { "@type": "MedicalCondition", "name": "Vinblastine", "code": { "@type": "MedicalCode", "code": "D014747", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.496.500.500.681.827.650" } } }, { "@type": "MedicalWebPage", "name": "Vincamine", "alternateName": "Vincamine", "url": "https://questionsmedicales.fr/mesh/D014749", "about": { "@type": "MedicalCondition", "name": "Vincamine", "code": { "@type": "MedicalCode", "code": "D014749", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.496.500.500.681.827.750" } } }, { "@type": "MedicalWebPage", "name": "Vincristine", "alternateName": "Vincristine", "url": "https://questionsmedicales.fr/mesh/D014750", "about": { "@type": "MedicalCondition", "name": "Vincristine", "code": { "@type": "MedicalCode", "code": "D014750", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.496.500.500.681.827.817" } } }, { "@type": "MedicalWebPage", "name": "Vindésine", "alternateName": "Vindesine", "url": "https://questionsmedicales.fr/mesh/D014751", "about": { "@type": "MedicalCondition", "name": "Vindésine", "code": { "@type": "MedicalCode", "code": "D014751", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.496.500.500.681.827.830" } } }, { "@type": "MedicalWebPage", "name": "Vinorelbine", "alternateName": "Vinorelbine", "url": "https://questionsmedicales.fr/mesh/D000077235", "about": { "@type": "MedicalCondition", "name": "Vinorelbine", "code": { "@type": "MedicalCode", "code": "D000077235", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.496.500.500.681.827.915" } } } ], "about": { "@type": "MedicalCondition", "name": "Alcaloïdes de Vinca", "alternateName": "Vinca Alkaloids", "code": { "@type": "MedicalCode", "code": "D014748", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Jaume Bastida", "url": "https://questionsmedicales.fr/author/Jaume%20Bastida", "affiliation": { "@type": "Organization", "name": "Grup de Productes Naturals, Departament de Biologia, Sanitat i Medi Ambient, Facultat de Farmàcia i Ciències de l'Alimentació, Universitat de Barcelona, Av. Joan XXIII, 27-31, Barcelona 08028, Spain." } }, { "@type": "Person", "name": "Sara Abouzeid", "url": "https://questionsmedicales.fr/author/Sara%20Abouzeid", "affiliation": { "@type": "Organization", "name": "Institute for Plant Biology, Technische Universität Braunschweig, Mendelssohnsstr. 4, 38106, Braunschweig, Germany; Pharmacognosy Department, Faculty of Pharmacy, Mansoura University, Mansoura, 35516, Egypt." } }, { "@type": "Person", "name": "Laura Lewerenz", "url": "https://questionsmedicales.fr/author/Laura%20Lewerenz", "affiliation": { "@type": "Organization", "name": "Institute for Plant Biology, Technische Universität Braunschweig, Mendelssohnsstr. 4, 38106, Braunschweig, Germany." } }, { "@type": "Person", "name": "Dirk Selmar", "url": "https://questionsmedicales.fr/author/Dirk%20Selmar", "affiliation": { "@type": "Organization", "name": "Institute for Plant Biology, Technische Universität Braunschweig, Mendelssohnsstr. 4, 38106, Braunschweig, Germany. Electronic address: d.selmar@tu-bs.de." } }, { "@type": "Person", "name": "Rudolf Vrabec", "url": "https://questionsmedicales.fr/author/Rudolf%20Vrabec", "affiliation": { "@type": "Organization", "name": "ADINACO Research Group, Department of Pharmaceutical Botany, Faculty of Pharmacy, Charles University, Heyrovskeho 1203, 500 05, Hradec Kralove, Czech Republic; Department of Pharmacognosy, Faculty of Pharmacy, Charles University, Heyrovskeho 1203, 500 05, Hradec Kralove, Czech Republic." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Overall Survival for Esophageal Squamous Cell Carcinoma with Multiple Primary Cancers after Curative Esophagectomy-A Retrospective Single-Institution Study.", "datePublished": "2022-10-26", "url": "https://questionsmedicales.fr/article/36358682", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3390/cancers14215263" } }, { "@type": "ScholarlyArticle", "name": "Alpha-Ketoglutarate or 5-HMF: Single Compounds Effectively Eliminate Leukemia Cells via Caspase-3 Apoptosis and Antioxidative Pathways.", "datePublished": "2022-08-12", "url": "https://questionsmedicales.fr/article/36012295", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3390/ijms23169034" } }, { "@type": "ScholarlyArticle", "name": "Antimicrobial prophylaxis and the rate of blood stream infections and Clostridioides difficile in pediatric stem cell transplantation: A single-center retrospective study.", "datePublished": "2022-08-10", "url": "https://questionsmedicales.fr/article/35946349", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1111/petr.14375" } }, { "@type": "ScholarlyArticle", "name": "Impact of cell loss after warming of human vitrified day 3 embryos on obstetric outcome in single frozen embryo transfers.", "datePublished": "2022-07-20", "url": "https://questionsmedicales.fr/article/35857255", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s10815-022-02572-3" } }, { "@type": "ScholarlyArticle", "name": "Effect of regulatory T cells on short-term graft outcome in kidney transplant recipients, a prospective observational, single-center study.", "datePublished": "2022-05-25", "url": "https://questionsmedicales.fr/article/35643376", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.trim.2022.101630" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Composés hétérocycliques", "item": "https://questionsmedicales.fr/mesh/D006571" }, { "@type": "ListItem", "position": 3, "name": "Composés hétérocycliques à cycles fusionnés", "item": "https://questionsmedicales.fr/mesh/D000072471" }, { "@type": "ListItem", "position": 4, "name": "Composés hétérobicycliques", "item": "https://questionsmedicales.fr/mesh/D006574" }, { "@type": "ListItem", "position": 5, "name": "Indolizine", "item": "https://questionsmedicales.fr/mesh/D007212" }, { "@type": "ListItem", "position": 6, "name": "Indolizidines", "item": "https://questionsmedicales.fr/mesh/D054836" }, { "@type": "ListItem", "position": 7, "name": "Alcaloïdes indoliques", "item": "https://questionsmedicales.fr/mesh/D026121" }, { "@type": "ListItem", "position": 8, "name": "Alcaloïdes formés par condensation de sécologanine et de tryptamine", "item": "https://questionsmedicales.fr/mesh/D046948" }, { "@type": "ListItem", "position": 9, "name": "Alcaloïdes de Vinca", "item": "https://questionsmedicales.fr/mesh/D014748" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Alcaloïdes de Vinca - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Alcaloïdes de Vinca", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-06", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Alcaloïdes de Vinca", "description": "Comment les alcaloïdes de Vinca sont-ils diagnostiqués ?\nQuels tests sont utilisés pour évaluer l'efficacité des alcaloïdes ?\nLes alcaloïdes de Vinca sont-ils utilisés pour tous les types de cancer ?\nComment évaluer les effets secondaires des alcaloïdes ?\nLes tests génétiques sont-ils nécessaires pour les alcaloïdes de Vinca ?", "url": "https://questionsmedicales.fr/mesh/D014748?mesh_terms=Single-Cell+Analysis&page=1000#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Alcaloïdes de Vinca", "description": "Quels sont les effets secondaires courants des alcaloïdes de Vinca ?\nLes alcaloïdes de Vinca causent-ils des douleurs ?\nComment se manifestent les réactions allergiques aux alcaloïdes ?\nLes alcaloïdes de Vinca affectent-ils le système immunitaire ?\nQuels symptômes indiquent une surdose d'alcaloïdes de Vinca ?", "url": "https://questionsmedicales.fr/mesh/D014748?mesh_terms=Single-Cell+Analysis&page=1000#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Alcaloïdes de Vinca", "description": "Comment prévenir les effets secondaires des alcaloïdes de Vinca ?\nY a-t-il des précautions à prendre avant le traitement ?\nLes patients doivent-ils éviter certains aliments ?\nComment gérer le stress pendant le traitement ?\nLes vaccinations sont-elles recommandées avant le traitement ?", "url": "https://questionsmedicales.fr/mesh/D014748?mesh_terms=Single-Cell+Analysis&page=1000#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Alcaloïdes de Vinca", "description": "Comment les alcaloïdes de Vinca sont-ils administrés ?\nPeut-on combiner les alcaloïdes de Vinca avec d'autres traitements ?\nQuel est le rôle des alcaloïdes de Vinca dans le traitement du cancer ?\nLes alcaloïdes de Vinca nécessitent-ils une surveillance médicale ?\nQuels médicaments interagissent avec les alcaloïdes de Vinca ?", "url": "https://questionsmedicales.fr/mesh/D014748?mesh_terms=Single-Cell+Analysis&page=1000#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Alcaloïdes de Vinca", "description": "Quelles sont les complications possibles des alcaloïdes de Vinca ?\nLes alcaloïdes de Vinca peuvent-ils causer des problèmes cardiaques ?\nComment gérer une réaction sévère aux alcaloïdes de Vinca ?\nLes alcaloïdes de Vinca peuvent-ils affecter la fertilité ?\nQuelles sont les conséquences d'une surdose d'alcaloïdes de Vinca ?", "url": "https://questionsmedicales.fr/mesh/D014748?mesh_terms=Single-Cell+Analysis&page=1000#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Alcaloïdes de Vinca", "description": "Qui est à risque d'effets secondaires des alcaloïdes de Vinca ?\nLes antécédents médicaux influencent-ils le traitement ?\nLe mode de vie affecte-t-il la réponse au traitement ?\nLes interactions médicamenteuses augmentent-elles les risques ?\nLes femmes enceintes peuvent-elles utiliser des alcaloïdes de Vinca ?", "url": "https://questionsmedicales.fr/mesh/D014748?mesh_terms=Single-Cell+Analysis&page=1000#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment les alcaloïdes de Vinca sont-ils diagnostiqués ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Ils ne sont pas diagnostiqués, mais utilisés dans le traitement de cancers comme la leucémie." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour évaluer l'efficacité des alcaloïdes ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des tests sanguins et des examens d'imagerie sont utilisés pour évaluer la réponse au traitement." } }, { "@type": "Question", "name": "Les alcaloïdes de Vinca sont-ils utilisés pour tous les types de cancer ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Non, ils sont principalement utilisés pour des cancers spécifiques comme le lymphome et la leucémie." } }, { "@type": "Question", "name": "Comment évaluer les effets secondaires des alcaloïdes ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Les effets secondaires sont évalués par des examens cliniques et des rapports de symptômes." } }, { "@type": "Question", "name": "Les tests génétiques sont-ils nécessaires pour les alcaloïdes de Vinca ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Pas nécessairement, mais ils peuvent aider à personnaliser le traitement dans certains cas." } }, { "@type": "Question", "name": "Quels sont les effets secondaires courants des alcaloïdes de Vinca ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les effets secondaires incluent nausées, vomissements, et neuropathie périphérique." } }, { "@type": "Question", "name": "Les alcaloïdes de Vinca causent-ils des douleurs ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, ils peuvent provoquer des douleurs neuropathiques en raison de leur toxicité." } }, { "@type": "Question", "name": "Comment se manifestent les réactions allergiques aux alcaloïdes ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Les réactions allergiques peuvent se manifester par des éruptions cutanées ou des démangeaisons." } }, { "@type": "Question", "name": "Les alcaloïdes de Vinca affectent-ils le système immunitaire ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, ils peuvent entraîner une immunosuppression, augmentant le risque d'infections." } }, { "@type": "Question", "name": "Quels symptômes indiquent une surdose d'alcaloïdes de Vinca ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent des troubles neurologiques, des vomissements sévères et des convulsions." } }, { "@type": "Question", "name": "Comment prévenir les effets secondaires des alcaloïdes de Vinca ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Une hydratation adéquate et des médicaments antiémétiques peuvent aider à prévenir les nausées." } }, { "@type": "Question", "name": "Y a-t-il des précautions à prendre avant le traitement ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, informer le médecin des allergies et des médicaments en cours est crucial." } }, { "@type": "Question", "name": "Les patients doivent-ils éviter certains aliments ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Il n'y a pas d'aliments spécifiques à éviter, mais une alimentation équilibrée est recommandée." } }, { "@type": "Question", "name": "Comment gérer le stress pendant le traitement ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Des techniques de relaxation et un soutien psychologique peuvent aider à gérer le stress." } }, { "@type": "Question", "name": "Les vaccinations sont-elles recommandées avant le traitement ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des vaccinations peuvent être recommandées pour prévenir les infections pendant le traitement." } }, { "@type": "Question", "name": "Comment les alcaloïdes de Vinca sont-ils administrés ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Ils sont généralement administrés par voie intraveineuse dans un cadre hospitalier." } }, { "@type": "Question", "name": "Peut-on combiner les alcaloïdes de Vinca avec d'autres traitements ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Oui, ils sont souvent combinés avec d'autres agents chimiothérapeutiques pour une efficacité accrue." } }, { "@type": "Question", "name": "Quel est le rôle des alcaloïdes de Vinca dans le traitement du cancer ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Ils inhibent la division cellulaire, ralentissant la croissance des tumeurs malignes." } }, { "@type": "Question", "name": "Les alcaloïdes de Vinca nécessitent-ils une surveillance médicale ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une surveillance régulière est essentielle pour gérer les effets secondaires et ajuster le traitement." } }, { "@type": "Question", "name": "Quels médicaments interagissent avec les alcaloïdes de Vinca ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Certains antibiotiques et anticoagulants peuvent interagir, nécessitant une attention particulière." } }, { "@type": "Question", "name": "Quelles sont les complications possibles des alcaloïdes de Vinca ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent des infections, des saignements et des troubles neurologiques." } }, { "@type": "Question", "name": "Les alcaloïdes de Vinca peuvent-ils causer des problèmes cardiaques ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, ils peuvent entraîner des complications cardiaques, nécessitant une surveillance cardiaque." } }, { "@type": "Question", "name": "Comment gérer une réaction sévère aux alcaloïdes de Vinca ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Une réaction sévère nécessite une intervention médicale immédiate et l'arrêt du traitement." } }, { "@type": "Question", "name": "Les alcaloïdes de Vinca peuvent-ils affecter la fertilité ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, ils peuvent avoir un impact sur la fertilité, et des conseils en fertilité peuvent être nécessaires." } }, { "@type": "Question", "name": "Quelles sont les conséquences d'une surdose d'alcaloïdes de Vinca ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Une surdose peut entraîner des effets neurologiques graves et nécessite une prise en charge urgente." } }, { "@type": "Question", "name": "Qui est à risque d'effets secondaires des alcaloïdes de Vinca ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les patients âgés et ceux avec des antécédents de maladies neurologiques sont plus à risque." } }, { "@type": "Question", "name": "Les antécédents médicaux influencent-ils le traitement ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des antécédents de maladies hépatiques ou rénales peuvent influencer le dosage." } }, { "@type": "Question", "name": "Le mode de vie affecte-t-il la réponse au traitement ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, un mode de vie sain peut améliorer la tolérance et l'efficacité du traitement." } }, { "@type": "Question", "name": "Les interactions médicamenteuses augmentent-elles les risques ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certaines interactions peuvent augmenter les effets secondaires et les complications." } }, { "@type": "Question", "name": "Les femmes enceintes peuvent-elles utiliser des alcaloïdes de Vinca ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Non, leur utilisation est contre-indiquée pendant la grossesse en raison de risques pour le fœtus." } } ] } ] }

Sources (10000 au total)

Alpha-Ketoglutarate or 5-HMF: Single Compounds Effectively Eliminate Leukemia Cells via Caspase-3 Apoptosis and Antioxidative Pathways.

We recently showed that a combined solution containing alpha-ketoglutarate (aKG) and 5-hydroxymethyl-furfural (5-HMF) has a solid antitumoral effect on the Jurkat cell line due to the fact of its anti... The ONOO... aKG showed a concentration-dependent reduction in ONOO... Both substances showed high antioxidative potential in eliminating either peroxynitrite or nitration of tyrosine residues, which results in a better inhibition of cell growth and mitochondrial activit...

Antimicrobial prophylaxis and the rate of blood stream infections and Clostridioides difficile in pediatric stem cell transplantation: A single-center retrospective study.

The use of prophylactic antibiotics in the pre-engraftment period to minimize the risk of bacteremia is debatable given concerns of Clostridioides difficile (C. diff), antibiotics resistance, and disr... We retrospectively reviewed the rate and characteristics of bacteremia and C. diff infections within the first 100 days post-HSCT in all pediatric patients who received routine antibacterial prophylax... One hundred and thirty-five (100 allogeneic and 35 autologous) transplants in 123 patients were eligible for analysis. Median age at transplant was 7.1 (range 0.2-13.7), 67 (55%) were women, and diagn... The use of antibiotic prophylaxis was associated with low rate of bacteremia in the pre-engraftment period and a 10% risk of C. diff infections. More studies are needed to better evaluate the efficacy...

Impact of cell loss after warming of human vitrified day 3 embryos on obstetric outcome in single frozen embryo transfers.

Does cell loss (CL) after vitrification and warming (V/W) of day 3 embryos have an impact on live birth rate (LBR) and neonatal outcomes?... This retrospective analysis includes cleavage stage day 3 embryos vitrified/warmed between 2011 and 2018. Only single vitrified/warmed embryo transfers were included. Pre-implantation genetic screenin... On the total embryos (n = 2327), 1953 were fully intact (83.9%, group A) and 374 presented cell damage (16.1%, group B). In group B, 62% (232/374) of the embryos had lost only one cell. Age at cryopre... LBR is significantly higher after transfer of an intact embryo compared to an embryo with CL after warming; however, neonatal outcomes are comparable between the two groups....

Effect of regulatory T cells on short-term graft outcome in kidney transplant recipients, a prospective observational, single-center study.

Regulatory T cells (Tregs) are important for maintaining immune homeostasis, limiting kidney transplant rejection, and promoting transplant tolerance. Tregs are characterized as CD4 + CD25+ T cells an... This prospective observational study included 50 patients of both sexes, aged between 18 and 60 years, with end-stage renal disease (ESRD), and who underwent kidney transplantation at the Nizams Insti... The percentage of Tregs (Treg%) was significantly lower in ESRD patients before transplantation (baseline) than in the HCs [median 8.5% vs. 14.25%; p < 0.01]. After transplantation, Treg% decreased si... Within the first week after transplantation, the percentage of pre-transplant Tregs was significantly decreased compared to that in age- and sex-matched HC. The percentage of Tregs was also lower in p...

Comparative efficacy of different single drugs to prevent necrotizing enterocolitis in preterm infants: an update systematic review and network meta-analysis.

To investigate an optimal regimen of six drugs, including lactoferrin, probiotics, prebiotics, glutamine, arginine and erythropoietin (EPO), for the prevention of necrotizing enterocolitis (NEC) in pr... PubMed, Embase, Ovid, The Cochrane Library, and Web of Science databases were searched for randomized controlled trials (RCTs) investigating the efficacy of lactoferrin, probiotics, prebiotics, glutam... A total of 89 RCTs with 26,861 preterm infants were included. Arginine demonstrated the highest clinical efficacy in reducing the incidence of NEC, with probiotics being the next most effective and th... Existing literature highlights arginine as the most efficacious pharmacological agent in preventing NEC in preterm infants. It has been shown to effectively lower the rates of NEC, septicemia, and mor...

Vacuum-assisted wound closure and mesh-mediated fascial traction for temporary closure in open abdomen: A single-arm meta-analysis.

Open abdomen (OA) therapy is used in the management of patients who require surgery for severe abdominal conditions. This meta-analysis aims to evaluate the VAWCM technique regarding short and long-te... PubMed, Embase, and Cochrane Central were systematically searched for studies that analyzed VAWCM therapy in OA. Primary outcomes were the complete fascial closure rate and mean duration of OA treatme... Seven studies comprising 535 patients were included. We found a complete fascial closure rate of 77.3 per 100 patients (80.1%; 95% CI 59.6-88.7; I... Our findings showed that VAWCM is a viable option for OA treatment, successfully reaching complete fascial closure, with a low duration of the technique, even though it presented a high heterogeneity ...